×
S&P 500   4,131.20 (+1.81%)
DOW   32,991.92 (+1.09%)
QQQ   306.91 (+2.53%)
AAPL   148.49 (+3.28%)
MSFT   270.58 (+1.76%)
FB   193.92 (+1.20%)
GOOGL   2,229.79 (+3.43%)
AMZN   2,266.05 (+2.00%)
TSLA   752.23 (+6.29%)
NVDA   185.89 (+4.13%)
BABA   93.28 (-1.27%)
NIO   16.42 (+2.43%)
AMD   101.46 (+2.74%)
CGC   4.88 (-12.07%)
MU   73.02 (+3.43%)
T   21.22 (-0.47%)
GE   77.88 (+1.13%)
F   13.56 (+3.35%)
DIS   108.40 (+2.64%)
AMC   13.95 (+14.06%)
PFE   53.56 (-0.80%)
PYPL   84.95 (+5.63%)
NFLX   194.27 (+1.50%)
S&P 500   4,131.20 (+1.81%)
DOW   32,991.92 (+1.09%)
QQQ   306.91 (+2.53%)
AAPL   148.49 (+3.28%)
MSFT   270.58 (+1.76%)
FB   193.92 (+1.20%)
GOOGL   2,229.79 (+3.43%)
AMZN   2,266.05 (+2.00%)
TSLA   752.23 (+6.29%)
NVDA   185.89 (+4.13%)
BABA   93.28 (-1.27%)
NIO   16.42 (+2.43%)
AMD   101.46 (+2.74%)
CGC   4.88 (-12.07%)
MU   73.02 (+3.43%)
T   21.22 (-0.47%)
GE   77.88 (+1.13%)
F   13.56 (+3.35%)
DIS   108.40 (+2.64%)
AMC   13.95 (+14.06%)
PFE   53.56 (-0.80%)
PYPL   84.95 (+5.63%)
NFLX   194.27 (+1.50%)
S&P 500   4,131.20 (+1.81%)
DOW   32,991.92 (+1.09%)
QQQ   306.91 (+2.53%)
AAPL   148.49 (+3.28%)
MSFT   270.58 (+1.76%)
FB   193.92 (+1.20%)
GOOGL   2,229.79 (+3.43%)
AMZN   2,266.05 (+2.00%)
TSLA   752.23 (+6.29%)
NVDA   185.89 (+4.13%)
BABA   93.28 (-1.27%)
NIO   16.42 (+2.43%)
AMD   101.46 (+2.74%)
CGC   4.88 (-12.07%)
MU   73.02 (+3.43%)
T   21.22 (-0.47%)
GE   77.88 (+1.13%)
F   13.56 (+3.35%)
DIS   108.40 (+2.64%)
AMC   13.95 (+14.06%)
PFE   53.56 (-0.80%)
PYPL   84.95 (+5.63%)
NFLX   194.27 (+1.50%)
S&P 500   4,131.20 (+1.81%)
DOW   32,991.92 (+1.09%)
QQQ   306.91 (+2.53%)
AAPL   148.49 (+3.28%)
MSFT   270.58 (+1.76%)
FB   193.92 (+1.20%)
GOOGL   2,229.79 (+3.43%)
AMZN   2,266.05 (+2.00%)
TSLA   752.23 (+6.29%)
NVDA   185.89 (+4.13%)
BABA   93.28 (-1.27%)
NIO   16.42 (+2.43%)
AMD   101.46 (+2.74%)
CGC   4.88 (-12.07%)
MU   73.02 (+3.43%)
T   21.22 (-0.47%)
GE   77.88 (+1.13%)
F   13.56 (+3.35%)
DIS   108.40 (+2.64%)
AMC   13.95 (+14.06%)
PFE   53.56 (-0.80%)
PYPL   84.95 (+5.63%)
NFLX   194.27 (+1.50%)
LON:OVB

Ovoca Bio (OVB) Share Forecast, Price & News

GBX 10.50
-0.25 (-2.33%)
(As of 05/27/2022 03:16 PM ET)
Add
Compare
Today's Range
10.19
10.50
50-Day Range
9.77
14.85
52-Week Range
8.15
26
Volume
79,009 shs
Average Volume
172,409 shs
Market Capitalization
£8.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive OVB News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovoca Bio and its competitors with MarketBeat's FREE daily newsletter.

About Ovoca Bio

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.

Headlines

OVB.I - Ovoca Bio PLC Profile | Reuters
Ovoca Bio Share Chat
Ovoca Bio Share Price (OVB)
Ovoca Bio Regulatory News
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 10.64 per share
Book Value
GBX 20 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£8.56 million
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.06 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Ovoca Bio (LON:OVB) Frequently Asked Questions

Who are Ovoca Bio's key executives?
Ovoca Bio's management team includes the following people:
  • Mr. Kirill Andreyevich Golovanov, Interim Chairman & CEO (Age 44, Pay $199.72k)
  • Mr. Dmitriy Nikitashenko, VP of Fin.
  • Dr. Daniil Nemenov, Sr. VP of Clinical Devel. & Operations
  • Reneta Nikolova, Corp. Sec.
What other stocks do shareholders of Ovoca Bio own?
What is Ovoca Bio's stock symbol?

Ovoca Bio trades on the London Stock Exchange (LON) under the ticker symbol "OVB."

How do I buy shares of Ovoca Bio?

Shares of OVB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Ovoca Bio's stock price today?

One share of OVB stock can currently be purchased for approximately GBX 10.50.

How much money does Ovoca Bio make?

Ovoca Bio has a market capitalization of £8.56 million.

How many employees does Ovoca Bio have?

Ovoca Bio employs 5 workers across the globe.

What is Ovoca Bio's official website?

The official website for Ovoca Bio is www.ovocabio.com.

How can I contact Ovoca Bio?

The company can be reached via phone at 353 1 661 9819.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.